Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke | Zendy

Gregg C. Fonarow | Zendy; Eric E. Smith | Zendy; Jeffrey L. Saver | Zendy; Mathew J. Reeves | Zendy; Deepak L. Bhatt | Zendy; Maria V. GrauSepulveda | Zendy; DaiWai M. Olson | Zendy; Adrian F. Hernandez | Zendy; Eric D. Peterson | Zendy; Lee H. Schwamm | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke

Author(s) -

Gregg C. Fonarow,

Eric E. Smith,

Jeffrey L. Saver,

Mathew J. Reeves,

Deepak L. Bhatt,

Maria V. GrauSepulveda,

DaiWai M. Olson,

Adrian F. Hernandez,

Eric D. Peterson,

Lee H. Schwamm

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.110.974675

Subject(s) - medicine , stroke (engine) , tissue plasminogen activator , odds ratio , confidence interval , ischemic stroke , acute stroke , fibrinolytic agent , thrombolysis , emergency medicine , surgery , anesthesia , ischemia , myocardial infarction , mechanical engineering , engineering

The benefits of intravenous tissue-type plasminogen activator (tPA) in acute ischemic stroke are time dependent, and guidelines recommend an arrival to treatment initiation (door-to-needle) time of ≤60 minutes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research